Evidence map›Paper›PMID 40901847›Full record

ArticlePLOS global public health2025

Diabetes Mellitus screening and associated factors in Peru: A cross-sectional analysis of a national health survey.

Einer Carlos Eduardo Arevalo-Rios, Jennifer Layza-Reyes, Victor Hugo Noriega-Ruiz

Abstract read
In one paragraph

Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Einer Carlos Eduardo Arevalo-RiosAlberto Hurtado School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID https://orcid.org/0000-0001-8826-1560
Jennifer Layza-ReyesAlberto Hurtado School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID https://orcid.org/0009-0002-7366-4150
Victor Hugo Noriega-RuizAlberto Hurtado School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID https://orcid.org/0000-0003-4709-1328

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Screening rates for Type 2 diabetes mellitus (T2DM) in Peru remain low despite an increasing prevalence of the disease. In 2022, the American Diabetes Association (ADA) recommended screening adults aged 18-34 with overweight or obesity and at least one risk factor, including Latino ethnicity and lowered the universal screening age to 35 years. This study aimed to determine the T2DM screening prevalence in Peru and the factors associated with lack of screening in the population that meets ADA screening criteria. A cross-sectional, secondary data analysis was conducted based on the 2022 Peruvian Demographic and Health Survey database. Screening was defined as apparently healthy individuals having their blood glucose measured in the last year. Participants aged 18-34 years with overweight or obesity, as well as all participants aged ≥ 35 years, were included. Bivariate analysis was performed using the chi-squared test, and multivariate Poisson regression was used to estimate prevalence ratios (PRs), adjusting for potential confounders. Of 26,166 individuals who met inclusion criteria, 25.3% were screened for T2DM. The factors most strongly associated with lack of screening were: age 18-34 years (aPR: 1.08; 95% CI: 1.05-1.11), having only elementary education (aPR: 1.18; 95% CI: 1.13-1.23), not having health insurance (aPR: 1.15; 95% CI: 1.12-1.18), belonging to the lowest wealth quintile (aPR: 1.09; 95% CI: 1.05-1.13), and daily smoking (aPR: 1.10; 95% CI: 1.01-1.19). The national rate of screening for T2DM in Peru is low (25.3%). There is a higher prevalence for a lack of screening in people who: are younger, have only primary education, do not have health insurance, belong to the lowest wealth quintile, and are smokers. Targeted interventions are needed to improve screening coverage in these high-risk populations.

Identifiers

PMID40901847
PMCPMC12407462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.